Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Nuformix Plc LSE:NFX London Ordinary Share GB00BYW79Y38 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.10 -3.51% 2.75 1,758,083 09:28:50
Bid Price Offer Price High Price Low Price Open Price
2.70 2.80 2.85 2.75 2.85
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Nonequity Investment Instruments 0.54 -0.93 -0.16 14
Last Trade Time Trade Type Trade Size Trade Price Currency
14:12:48 O 24,027 2.705 GBX

Nuformix (NFX) Latest News

More Nuformix News
Nuformix Investors    Nuformix Takeover Rumours

Nuformix (NFX) Discussions and Chat

Nuformix Forums and Chat

Date Time Title Posts
18/1/202100:26Nuformix plc7,204
08/1/202101:50****NFX2021****-

Add a New Thread

Nuformix (NFX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-01-18 14:12:502.7124,027649.93O
2021-01-18 13:34:222.801,77649.73O
2021-01-18 12:56:572.711,28434.73O
2021-01-18 12:54:222.7122,722614.63O
2021-01-18 12:28:542.7829,164810.73O
View all Nuformix trades in real-time

Nuformix (NFX) Top Chat Posts

DateSubject
18/1/2021
08:20
Nuformix Daily Update: Nuformix Plc is listed in the Nonequity Investment Instruments sector of the London Stock Exchange with ticker NFX. The last closing price for Nuformix was 2.85p.
Nuformix Plc has a 4 week average price of 2.55p and a 12 week average price of 2.55p.
The 1 year high share price is 9.35p while the 1 year low share price is currently 2.55p.
There are currently 513,359,368 shares in issue and the average daily traded volume is 2,878,965 shares. The market capitalisation of Nuformix Plc is £14,117,382.62.
14/1/2021
23:12
soupdragon55: It means Ebers will raise cash, they can then pay for more patent work from NFX. After that they can pay for development of the product and pay NFX milestones as per the £51m contract, then royalties follow. Ebers sole business plan uses NFX to generate the IP.
14/1/2021
21:08
soupdragon55: Jackpot, NFX movement today caused by us finding out Ebers Tech are reversing into TSX listed Kelly Ventures raising $53m. Https://www.stockwatch.com/News/Item?bid=Z-C:KKL-3008857&;symbol=KKL&region=C 2020-12-21 16:37 ET - News Release Mr. Paul Larkin reports KELLY VENTURES TO ACQUIRE EBERS TECH INC. AS QUALIFYING TRANSACTION Kelly Ventures Ltd. has signed a letter of intent (LOI), dated Dec. 18, 2020, pursuant to which the company will acquire all of the outstanding shares of Ebers Tech Inc. The parties intend to complete a business combination or other similarly structured transaction which will constitute a reverse takeover of Kelly Ventures. The proposed transaction is intended to be an arm's-length qualifying transaction (QT) for the company as defined under TSX Venture Exchange policies. Ebers is a Canadian-registered pharma tech company, with a portfolio of patents and development methods for producing cocrystals. Ebers is strategically positioned at the nexus of the big pharmaceutical and cocrystal industries, enabling the company to play a crucial role in the development of the next generation of pharmaceuticals and therapies and to simultaneously exploit the rapidly advancing cannabinoid and psilocybin cocrystal, pharmaceutical and wellness areas. Of these, the most widely studied and used application is in drug development and, more specifically, the formation, design and implementation of active pharmaceutical ingredients (API).
14/1/2021
14:21
for fx sake: Any idea how dependent Ebers is on NFX (i.e how much of 53m valuation is down to NFX co-crystal IP)?
23/12/2020
17:06
frogyboyo: Happy Christmas to you all. Let's pray the share price is many times higher this time next year.However I predict there will be no NFX this time next year which SHOULD be a good thing for us!!
20/11/2020
10:39
for fx sake: Yep. I expect there is little chance of that ever coming to light though even if it was the underlying cause of the damage done to the share price.
16/11/2020
12:31
gibso6767: I now block any soothsayer that’s heard ‘ whispers ‘ or ‘ Rumours ‘ or even ‘ rumours of rumours ‘ and on a regular if not daily basis tell those in particular on twitter what I think of them ( I never get a reply either to my questioning of their tweet or additional ridiculing of the same ). I’d like to think that rules in place and a minuscule workforce does not now carer for suchlike. And in reflection the Times Article has caused horrific damage to NFX as a company and to many shareholders( still more than a year later ) Hopefully NFX can release any news now that 1/Actually in Existence 2/Release without other knowing prior of its release and content . Would also like to see Nfx update shareholders register in time and properly .
10/10/2020
12:55
albert arthur: This is why I'm excited about NFX, the cap is 14m they are listed on the main market, the float is 27%, the price is near placing price, that's just to get started.. NFX repurpose drugs, they have placed it seems to repurpose NXP002 to be inhaled for the treatment of ARDS and Cytokine Storm, like the TILS drug. ARDS and Cykotine storm is what kills people it many diseases such as AIDS, COVID19 and many others. Like the TILS IL6 drug.See this:https://www.europeanreview.org/wp/wp-content/uploads/9169-9171.pdfhttp://www.pharmaceuticaldaily.com/nuformix-wraps-up-pilot-study-for-its-nxp002-for-treating-fibrosis/Also this text from the placing RNS:An ambition of the Board is development of some of the Group assets for the treatment of Covid-19. The Board has previously confirmed, in conjunction with its network of key opinion leaders, that it had started to review and assess emerging academic data that suggests coronaviruses can trigger hyperinflammation through activation of the biological target known as the NLRP3 inflammasome, making NXP002 a potential novel drug target to treat Covid-19. This, together with potential future licensing opportunities for NXP002 in both IPF and Covid-19, makes it important to explore all licensing possibilities to maximise value for shareholders. Business development opportunities will therefore be expanded, to exploit the potential for licensing NXP002 for global markets, to continue to pursue licensing opportunities identified for the Asian market, and to explore potential development interest in the treatment of Covid-19.Now watch this video, Phernominal opportunities. Also talks of inhaler:https://youtu.be/K5wMQ2rCrHsNFX drug repurpose specialist:Cap 14mMain market.Float 27%Forecast FT 227%Cash raised 650k.n
24/9/2020
06:20
peverill: At last!!,Appears to be a win win situation for NFX.While not the blockbuster we are waiting for,it should underpin the share price and make anyone else looking at their wares move a little quicker in the deal process.Hopefully the rest will follow.
22/8/2020
08:18
pennyfalls: Hi Soup, So there wasn't more to it than that about any possible deal? You sounded like you had specific information, so that was a little naughty of you, especially with what you say about rampers. I've also got to comment on something you said on LSE, when you stated that all posters only post because they want to effect movement in share price. to be honest I'm sick of living in this binary world where there's only good or bad, or one position or another. I actually post, and I hope some others do too, because they like sharing information and hearing other views. I also have liked countering outright lies on the boards, and I also do it as a personal learning process. So so maybe you post to change the share price but I don't.
21/5/2020
10:35
barrythefish: Look, for once and all charts are utterly useless on news dependant stocks like this. For Microsoft, Apple etc yes they may have a place but nfx share price is effected by one thing and one thing only - News.Positive news = increaseNegative news= decreaseNo news = slow decrease
Nuformix share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
NFX
Nuformix
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210119 00:35:37